2017 American Transplant Congress
De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.
Previous studies reported that tacrolimus (TAC) with high-dose sirolimus (SRL) was associated with worse outcomes in kidney transplantation, compared to TAC with mycophenolate mofetil (MMF.).…2017 American Transplant Congress
Resumption of Standard Dose Immunosuppression Following Resolution of BK Viremia Does Not Lead to Viremia Recurrence.
Medicine, Nephrology, University of Florida, Gainesville, FL
Introduction: Reduction of immunosuppression (IS) in response to BK viremia following kidney transplantation prevents the development of BK virus nephropathy, with no apparent increase in…2017 American Transplant Congress
Long-Term Drug-Free Survival of Tiny Cynomolgus Islet Allografts.
Following upon highly beneficial effects observed with short-term alpha 1-antitrypsin (AAT) treatment in the marginally sized autologous cynomolgus islet transplant model, we are testing the…2017 American Transplant Congress
Successful Launch of an ABO-Incompatible Kidney Transplantation Program to Overcome the Shortage of Compatible Living Donors: Experience at a Single Center.
Introduction:ABO-incompatible (ABOi) kidney transplantation (KT) is being increasingly performed to overcome donor shortages. However, debate persists regarding the post-transplant outcomes of ABOi KT versus that…2017 American Transplant Congress
Antiretroviral Therapy Modification of HIV+ Patients Listed for Kidney Transplantation.
Introduction:HIV+ individuals can receive kidney transplant (KT) safely and effectively but face additional challenges from potential drug interactions between antiretroviral therapy (ART) and immunosuppression(IS). Little…2017 American Transplant Congress
Immunosuppressant Costs for Medicare Part D and Kidney Transplant Recipients Since the Introduction of Generic Formulations in an Incident Kidney Transplant Population.
Background: Substitution of generics (GEN) for brand name (BN) immunosuppressants (IS) has increased in kidney transplant recipients (KTR) since the introduction of GEN mycophenolate mofetil…2017 American Transplant Congress
Systemic Immunosuppression in the Setting of Ocular Surface Stem Cell Transplantation.
1University of Cincinnati, Cincinnati, OH; 2Cincinnati Eye Institute, Cincinnati, OH
Purpose: To evaluate the success, tolerability, and side effects of systemic immunosuppression (SI) in patients undergoing ocular surface stem cell transplantation (OSST) under the SI…2017 American Transplant Congress
Medication Adherence and Medicare B Coverage Among Transplant Recipients.
Purpose: Impact of nonadherence among transplant recipients has been well documented as a significant contributor of allograft failure. Medicare covers immunosuppressive medications for eligible patients…2017 American Transplant Congress
Comparison of Long Term Survival Outcomes for Everolimus (EVR) vs. Mycophenolic Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant.
In the US, MPA in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine A [CsA]) is the most commonly used maintenance immunosuppressive therapy post…2017 American Transplant Congress
More Than Renal Function: Use of Belatacept to Improve Drug Toxicities.
Background: Data with belatacept has demonstrated that patients on de novo belatacept have better renal function and improved patient and graft survival seven years post-transplant.…
- « Previous Page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- …
- 138
- Next Page »